Clinical Trial

A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Study acronym: ELEVATION
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, single arm, open-label study. The purpose of the study is to evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of Prizlon-cel (Phase 2) in patients with relapsed or refractory large b-cell lymphoma (LBCL).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-03-24; most recent amendment 2025-12-23.
Trial Details
NCT Number NCT05800977
Lead Sponsor Shanghai AbelZeta Ltd.
Conditions Relapsed/Refractory Large B-Cell Lymphoma
Enrollment 112 participants
Start Date 2023-02-22
Primary Completion 2027-03-31 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-31